Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Recordati Rare Diseases Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11332
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Recordati Rare Diseases Inc (RRD), a subsidiary of Recordati SpA is a biopharmaceutical company that discovers and develops orphan drugs and biologics. The company’s products comprise chemet, neoprofen, panhematin, desoxyn, mustargen, carbaglu, cosmegen, peganone and tranxene, among others. It offers its products in the forms of capsules, injections and tablets. RRD’s products are used in the treatment of rare diseases such as acute intermittent porphyria, patent ductus arteriosus, Wilms’ tumor, NAGS deficiency, nonseminomatous testicular cancer, and others. The company markets its products through its distributors located across the US, Canada and others. RRD is headquartered in Lebanon, New Jersey, the US.

Recordati Rare Diseases Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Partnerships 11
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc – Key Competitors 13
Recordati Rare Diseases Inc – Key Employees 14
Recordati Rare Diseases Inc – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Key Facts 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recordati Rare Diseases Acquires North American Rights to Cystadane 10
Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 11
Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 12
Recordati Rare Diseases Inc, Key Competitors 13
Recordati Rare Diseases Inc, Key Employees 14

List of Figures
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recordati Rare Diseases Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Development Bank of Southern Africa:企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Landstar System, Inc.:企業の戦略・SWOT・財務分析
    Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report Summary Landstar System, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Gerdau S.A.:企業の戦略・SWOT・財務情報
    Gerdau S.A. - Strategy, SWOT and Corporate Finance Report Summary Gerdau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • TransGlobe Energy Corp (TGL):企業の財務・戦略的SWOT分析
    Summary TransGlobe Energy Corp (TransGlobe Energy) is an oil and gas company that explores, develops and produces crude oil and natural gas. The company develops oil and natural gas properties in the Arab Republic of Egypt and the Republic of Yemen. It holds interests in various production sharing c …
  • Petroleum, Oil and Gas Corporation of South Africa (SOC) Ltd-石油・ガス分野:企業M&A・提携分析
    Summary Petroleum, Oil and Gas Corporation of South Africa (SOC) Ltd (PetroSA) a subsidiary of CEF SOC Limited, is an integrated oil and gas company. It explores and produces oil and natural gas resources. The company operates Jubilee, Oribi, and Oryx oil fields; F-A and F-A Satellite, E-M and E-M S …
  • Unimedic AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Unimedic AB (Unimedic), formerly Ergobe Pharma AB, a subsidiary of MedCap AB, is a pharmaceutical company which develops, manufactures, distributes and markets pharmaceutical products. The company offers non-licensed, extemporaneous, and licensed pharmaceuticals targeting the therapy areas w …
  • AFC Energy plc (AFC):企業の財務・戦略的SWOT分析
    Summary AFC Energy Plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. Its power generation technology is used in the industrial markets and produces heat, water, and electricity. AFC Energy provides its electricity for industrial applicati …
  • Bharat Road Network Ltd (BRNL):企業の財務・戦略的SWOT分析
    Bharat Road Network Ltd (BRNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • BellBrook Labs LLC-医療機器分野:企業M&A・提携分析
    Summary BellBrook Labs LLC (BellBrook) is a medical device company that develops detection reagents and screening tools. The company’s biochemical assay technology offers UVO microconduit array platform, chemotaxis assay plate, transcreener HTS assays, ADP² assays, AMP² and GMP² assays, GDP assays, …
  • Sandoz International GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Sandoz International GmbH (Sandoz), a subsidiary of Novartis AG develops, manufactures and commercializes generic pharmaceutical products. The company provides biosimilars, generic antibiotics, dermatology and transplantation medicines. Its biosimilars comprise Omnitrope, Binocrit and Zarzio …
  • GLG Life Tech Corp (GLG):企業の財務・戦略的SWOT分析
    GLG Life Tech Corp (GLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Chubu Electric Power Co Inc (9502):石油・ガス:M&Aディール及び事業提携情報
    Summary Chubu Electric Power Co Inc (Chubu) is an energy utility. It generates and procures electricity; and offers electric network related services. The company produces electricity using hydro, thermal, nuclear and renewable sources. Chubu has interests in upstream and midstream energy fields. It …
  • New Zealand Post Ltd:企業の戦略的SWOT分析
    New Zealand Post Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Institut Gustave Roussy-製薬・医療分野:企業M&A・提携分析
    Summary Institut Gustave Roussy (IGR) is a cancer research institute that offers healthcare services to patients suffering from cancer and conducts research to identify new therapies. The institute provides treatment for the diseases that include endocrine tumours, childhood cancer, gynecological ca …
  • Atrium Innovations Inc-製薬・医療分野:企業M&A・提携分析
    Summary Atrium Innovations Inc (Atrium) is a provider of science-based natural health products. The company develops, manufactures and markets nutritional and dietary supplements. Its major products include minerals, vitamins and specialized products such as enzymes and probiotics. Atrium markets it …
  • Dhofar Tourism Company SAOG:企業の戦略・SWOT・財務情報
    Dhofar Tourism Company SAOG - Strategy, SWOT and Corporate Finance Report Summary Dhofar Tourism Company SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Arthur J. Gallagher & Co:企業の戦略・SWOT・財務情報
    Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report Summary Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Raiffeisen Bank International AG:企業の戦略・SWOT・財務情報
    Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SmartCool Systems Inc (SSC):企業の財務・戦略的SWOT分析
    Summary SmartCool Systems Inc (SmartCool Systems) is a clean technology company that manufactures and sells energy and cost reduction technologies. The company’s products include ECO3, ESM, and soft solutions. Its ECO3 and ESM are retrofit technologies that reduce the energy consumption of compresso …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆